Albert D Mason Inc. Has $931,000 Stake in Iradimed Corporation (NASDAQ:IRMD)

Albert D Mason Inc. raised its position in shares of Iradimed Corporation (NASDAQ:IRMD) by 15.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,936 shares of the medical equipment provider’s stock after acquiring an additional 2,277 shares during the quarter. Albert D Mason Inc.’s holdings in Iradimed were worth $931,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of Iradimed by 70.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 29,226 shares of the medical equipment provider’s stock worth $1,470,000 after buying an additional 12,051 shares during the period. Principal Financial Group Inc. bought a new position in Iradimed during the third quarter worth $246,000. Wilmington Savings Fund Society FSB acquired a new stake in Iradimed in the third quarter worth $126,000. Barclays PLC grew its holdings in Iradimed by 113.9% in the third quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock worth $1,196,000 after purchasing an additional 12,657 shares during the period. Finally, Stifel Financial Corp increased its stake in Iradimed by 9.8% in the third quarter. Stifel Financial Corp now owns 24,428 shares of the medical equipment provider’s stock valued at $1,229,000 after purchasing an additional 2,174 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Iradimed Price Performance

IRMD stock opened at $59.17 on Friday. The company’s 50-day moving average is $54.76 and its 200-day moving average is $50.12. The stock has a market capitalization of $749.68 million, a PE ratio of 40.53 and a beta of 0.81. Iradimed Corporation has a 1 year low of $40.18 and a 1 year high of $59.31.

Iradimed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were issued a $0.15 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 1.01%. Iradimed’s payout ratio is currently 41.10%.

Insider Buying and Selling at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.